Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by UroGen Pharma Ltd.
< Previous
1
2
3
Next >
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
October 30, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
October 28, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
October 15, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Appoints Chris Degnan as Chief Financial Officer
October 09, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
October 02, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
September 16, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Present at Upcoming Investor Conferences
August 29, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
August 14, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
August 13, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
August 05, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
June 17, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
June 13, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
June 06, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
June 05, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
June 03, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
May 22, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
May 13, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Participate at Upcoming Investor Conferences
May 07, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
May 05, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
May 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
May 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
May 03, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
April 17, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
April 15, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
April 03, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
March 14, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
March 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.